Kalamazoo Pride drew tens of thousands this year, despite fewer sponsors and a changing political landscape. The festival was ...

On May 13th, 1980, an F3 tornado traveled 11 miles from the west side of Kalamazoo through downtown before lifting near Comstock. Five people were killed and 79 were seriously injured. Bronson Park, ...

The U.S. Immigration and Customs Enforcement conducted a raid in Paramount on Saturday morning, a day after federal agents raided several locations across Los Angeles. Large groups of protesters ...

OTSEGO TWP. — The body of a man was recovered from the Kalamazoo River by the Allegan County Sheriff's Office on Tuesday, May 27, in Otsego Township. According to police, there was no indication ...

It's been a tough go for Pfizer (NYSE: PFE). Shares of the pharmaceutical giant are down over 60% from their highs, a multi-year slide since pandemic-related sales peaked a few years ago.

US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

It did not take long for Pfizer Inc. (NYSE:PFE) to change its mind on its oncology pipeline approach – after the deal with Summit Therapeutics Inc. (SMMT) in February for co-development of ...

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

Emilio Parra Doiztua / Bloomberg / Getty Images Pfizer said late Monday that it has agreed to a deal to help develop and market a Chinese cancer drug across the globe. Chinese firm 3SBio is ...

Pfizer announces a licensing agreement with 3SBio to develop, manufacture and commercialize SSGJ-707 globally, excluding China. Get the Strategy to Trade Pre-Fed Setups and Post-Fed Swings—Live ...

Pfizer's licensing deal with China's 3Sbio for PD-1/VEGF antibody has an upfront payment more than double what Merck paid last year for its deal with China's LaNova Pfizer Inc. plans to spend ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...